Poster
First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
Author
Richard Kim
Condition
hepatocellular carcinoma
Drug target
FGFR4
Drug moa
FGFR4 inhibitor
Source url
s3://convoke-optic-posters/2024-05-10/BLU-554-Poster-Presentation-by-Blueprint-Medicines-on-November-29-2016-at-the-EORTC-NCI-AACR-Symposium-1.pdf
9 organizations
1 product
Product
FisogatinibOrganization
Moffitt Cancer CenterOrganization
UCL Cancer InstituteOrganization
Vall d’Hebron Institute of OncologyOrganization
National Cancer Center SingaporeOrganization
Asan Medical CenterOrganization
Huntsman Cancer CenterOrganization
Guy’s HospitalOrganization
Mount Sinai Medical CenterOrganization
Blueprint Medicines